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Kathryn B. Garber1,*Mitochondrial Heteroplasmy Is Normal
Each cell in the body contains several mitochondria,
which themselves contain multiple copies of the mtDNA.
When a mitochondrial disorder is caused by an mtDNA
mutation, the concept of heteroplasmy, or the presence
of more than one distinct population of mtDNA, is key.
Because mitochondria segregate randomly to daughter
cells, the relative amount of mutant:normal mtDNA can
vary widely between affected individuals within a family
and between tissues within an affected individual. These
features affect the phenotype and the recurrence risk in
the family. In contrast, it is generally held that normal
individuals have homogeneous mtDNA, or homoplasmy.
Instead, He et al. ﬁnd that normal individuals also have
mtDNA heteroplasmy, as revealed by high-throughput
sequencing of mtDNA from ten normal individuals.
Each sample had, on average, four heteroplasmic variants,
but each variant was not present in all tissues examined,
and the level of heteroplasmy sometimes varied widely
between tissues in a single individual. Segregation of
heteroplasmic variants within families indicates that
some of the variation in normal individuals is maternally
inherited, whereas other variants arise as somatic muta-
tions during development. Even more mtDNA variation
arises in tumors. Matched colorectal cancer samples were
compared to normal tissue and found to have additional
homplasmic and heteroplasmic variation that might be
useful for monitoring tumors.
He et al. (2010). Heteroplasmic mitochondrial DNA muta-
tions in normal and tumour cells. Nature, in press. Published
online March 3, 2010. 10.1038/nature08802.Survival Estimates for Children with Congenital
Anomalies
‘‘Will they be okay?’’ is surely a question that parents of
a newborn child with a congenital anomaly ask their
healthcare providers. Unfortunately, particularly for more
rare anomalies, good data are often not available to be
provided to parents. A recent population-based study of
congenital anomalies in the UK will go a long way toward
changing that. The UK Northern Congenital Abnormality
Survey (NorCAS) is a population-based register of con-
genital anomalies for northern England. Tennant et al.
matched the NorCAS data with hospital and national
mortality records to estimate survival rates for a large range1Department of Human Genetics, Emory University School of Medicine, Atlan
*Correspondence: kgarber@genetics.emory.edu
DOI 10.1016/j.ajhg.2010.03.006. ª2010 by The American Society of Human
The Amof congenital anomalies, some as far as 20 years. This
study included more than 13,000 cases of congenital
anomaly that were referred to NorCAS between 1985 and
2003. Unlike other, similar studies, the authors consider
the inﬂuence of associated anomalies in their estimates
through use of a hierarchical classiﬁcation system. This
system allowed them to more accurately estimate survival
for particular subtypes of anomalies. For example, they
report the 20-year survival for isolated ventricular septal
defect to be greater than 98%, but it would have been
91.7% had they not separately classiﬁed individuals with
syndromic cases or multiple anomalies. This work will no
doubt serve as a valuable resource for healthcare profes-
sionals guiding families who are affected by congenital
anomalies.
Tennant et al. (2010). 10-year survival of children born with
congenital anomalies: A population-based study. The Lancet
375, 649–656.Breathing Easy
Although the underlying problem in cystic ﬁbrosis (CF) is
the absence of a chloride channel, the real pathologic issue
is one of mucus—thick, excessive mucus that clogs the
lungs, the pancreatic ducts, and the bowel. In a mouse
model of CF, Harmon et al. show that, at least in the colon,
the diabetes drug rosiglitazone can suppress this mucus
accumulation. The authors started down this avenue of
research with the ﬁnding that Cftr/ mice have a defect
in PPAR-dependent gene expression in their colons. Rosi-
glitazone, a known PPAR-g agonist, normalizes expression
of several genes and vastly improves survival of themutant
mice, who normally die within 6 weeks of life because of
intestinal or colonic obstruction. Expression of PPAR-g
itself is normal in Cftr/mice; it is instead the production
of its activating ligand 15-keto-prostaglandin-2 that is
reduced, as a result of lower expression of the dehydroge-
nase that produces this lipid. Ultimately, the effects of
rosiglitazone on PPAR-g signaling do not improve chloride
secretion in Cftr/ mice but, rather, reduce mucus vis-
cosity by increasing bicarbonate secretion, which is deﬁ-
cient in individuals with CF because of the role of the CFTR
channel in bicarbonate and chloride exchange. This work
not only outlines a pathway to explain the production of
excess mucus in CF but also suggests PPAR-g as a thera-
peutic target for intervention in this devastating disorder.ta, GA 30322, USA
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Harmon et al. (2010). Pharmacological correction of a defect
in PPAR-g signaling ameliorates disease severity in Cftr-deﬁ-
cient mice. Nature Medicine 16, 313–318.
Blame It on Mom and Dad
The integration of mobile elements in the human genome
has been an important force in its evolution, so viral inte-
gration is not a novel phenomenon. When we think of the
viral integration that occurs in our population now, as
with retroviruses, the inheritance of these integrated
elements isn’t considered because it occurs in somatic
cells. Apparently, it can happen. Arbuckle et al. recently
found families in which integrated human herpesvirus-6
(HHV-6) has been inherited. HHV-6A seems to integrate
speciﬁcally into telomeres via homologous recombination,
using a perfect TTAGGG telomere repeat in its genome.
Fluorescence in situ hybridization on peripheral-blood
mononuclear cells was used to document the insertion of
the virus into telomeric segments, and this occurred on
a different chromosome in each of the three families in
the study. Within a family, multiple individuals had the
same viral strain at the same integration site, so HHV-6 is
presumed to have been inherited through the family.
Moreover, HHV-6 could be reactivated from peripheral-
blood cultures from these individuals, despite the absence
of free viral genomes in these cells. HHV-6 is a ubiquitous
virus that is believed to cause disease mainly in immuno-
suppressed or immunocompromised individuals. As yet,
the consequences of HHV-6 integration and inheritance
are unclear, and we do not know how widespread this
phenomenon is.
Arbuckle et al. (2010). The latent human herpesvirus-6A
genome speciﬁcally integrates in telomeres of human chromo-
somes in vivo and in vitro. PNAS, in press. Published online
March 8, 2010. 10.1073/pnas.0913586107.504 The American Journal of Human Genetics 86, 503–505, April 9, 2A Murky Crystal Ball
Do you want to know your future? Several personal geno-
mics companies will provide you with a risk assessment
for various disorders, based on your genotype at several
markers. These companies use data from population-based
genetic association studies to identify markers whose allele
distribution differs between people with a certain pheno-
type and those without. The problem is that the prospec-
tive value of this genetic information on an individual
level is not clear. Paynter et al. assessed the prospective
value of genetic-risk scores for cardiovascular disease in
a systematic way. Using the National Human Genome
Research Institute’s Catalog of Published Genome-Wide
Association Studies, they collected all SNPs associated
with cardiovascular disease or its intermediate phenotypes
and used them to calculate genetic-risk scores for cardio-
vascular disease in a prospective study of more than
19,000 women who were followed for a median of 12 years
for cardiovascular disease events. After adjustment for
traditional risk factors, the genetic-risk scores that they
calculated were not associated with incident cardiovas-
cular disease. In fact, self reports of family history of heart
attack were better able to predict risk of a cardiovascular
event in this group of women than were the genetic-
risk scores. For each individual, the authors calculated
genetic-risk scores by summing the number of risk alleles
at all of the included SNPs. In the future, perhaps we will
better understand how to combine and use this type of
genotype information in a way that provides more accu-
rate genetic-risk assessments for disease. For now, the
view through our genetic crystal ball for complex traits
remains pretty murky.
Paynter et al. (2010). Association between a literature-based
genetic risk score and cardiovascular events in women. JAMA
303, 631–637.This Month in our Sister JournalsACE Modiﬁes the Pompe Phenotype
Because heterogeneity in the age of onset and the severity of
the disease course for the non-infantile forms of Pompe
disease does not always correlate with the level of residual
acid alpha-glucosidase activity, it is believed thatmodifying
genes inﬂuence the clinical course of this glycogen storage
disorder. Non-infantile Pompe is characterized by progres-
sive muscle weakness, which led Filippi et al. to consider
candidate modifying genes based on their association
with muscle function. A well-known insertion/deletion
(I/D)polymorphism in the gene encoding angiotensin-con-
verting enzyme (ACE) has been found by some researchers
to associate with muscle strength and physical perfor-
mance.Amonga sampleof38peoplewith late-onsetPompe
disease, theACEDDgenotypewas associatedwith an earlier
onsetofdiseaseand fasterdiseaseprogression.TheDallele isassociated with increased ACE activity, which promotes
vasoconstriction. The authors postulate that themodifying
effect of theACEpolymorphismcouldbedue to the reliance
of Pompe-affected muscle tissue on circulating glucose as
a result of its inability to use stored glycogen.
Filippi et al. (2010). The angiotensin-converting enzyme
insertion/deletion polymorphism modiﬁes the clinical outcome
in patients with Pompe’s disease. Genetics in Medicine, in press.
Published online March 19, 2010. 10.1097/GIM.0b013
e3181s2900e.
Modiﬁers of Polyglutamine Aggregation
The intracellular aggregation of polyglutamine-containing
huntingtin protein is a well-recognized hallmark of
Huntington disease. Although these aggregates appear to
be intimately linked to the disease, much remains to be010
understood about their formation and role in neurodegen-
eration. Zhang et al. developed a quantitative ﬂuorescence
microscopy assay to measure aggregate formation in a
Drosophila cell-based assay and performed a genome-wide
RNAi screen to identify modiﬁers of aggregate formation.
More than 100 genes were validated in their screens,
including both enhancers and suppressors of aggregate
formation. These include genes with a variety of functions,
including protein biogenesis, cytoskeleton and protein
trafﬁcking, chaperones, signaling, and nonsense-mediated
decay. Two of the aggregation-modifying genes were tested
in a Drosophila model of Huntington disease neurodegen-The Ameration, and both also modiﬁed the neurotoxicity of poly-
glutamine-containing huntingtin. Additionally, homologs
of several of their aggregation modiﬁers have previously
been reported by other groups to modify toxicity of poly-
glutamine and other aggregate-associated disorders. Thus,
the modiﬁers identiﬁed in this screen may have relevance
for toxicity as well as aggregation of polyglutamine-con-
taining huntingtin.
Zhang et al. (2010). A genome-wide RNAi screen formodiﬁers
of aggregate formation by mutant huntingtin in Drosophila.
Genetics, in press. Published online January 25, 2010.
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